AI Engines For more Details: Perplexity Kagi Labs You
Local Anesthetic: Oxethazaine works by blocking nerve impulses responsible for pain sensation in the affected area. It is commonly used topically to numb the mucous membranes of the mouth and throat, providing temporary relief from sore throat, mouth ulcers, gingivitis, and other oral discomforts.
Oral Pain Relief: Oxethazaine is often included in formulations such as mouthwashes, lozenges, sprays, and gels for the treatment of minor mouth and throat irritations, including pain caused by dental procedures, canker sores, sore throat, and minor mouth injuries.
Anti-inflammatory Properties: In addition to its anesthetic effects, oxethazaine may possess mild anti-inflammatory properties, helping to reduce inflammation and swelling in the oral mucosa.
Fast Onset of Action: Oxethazaine typically provides rapid onset of pain relief when applied locally to the affected area, making it suitable for short-term symptomatic relief of oral discomfort.
Minimal Systemic Absorption: When used topically as directed, oxethazaine is poorly absorbed through the mucous membranes, resulting in minimal systemic exposure and reduced risk of systemic side effects.
Temporary Relief: It's important to note that oxethazaine provides temporary relief of symptoms and is not intended for long-term use or treatment of underlying medical conditions. Persistent or severe oral pain should be evaluated by a healthcare professional to determine the underlying cause and appropriate treatment.
Safety Considerations: While oxethazaine is generally considered safe when used as directed, allergic reactions or local irritation may occur in some individuals. It should not be used in patients with known hypersensitivity to local anesthetics or any of its components. Care should be taken to avoid ingestion of oxethazaine-containing products.
Consultation with Healthcare Provider: Before using oxethazaine-containing products, individuals with pre-existing medical conditions, pregnant or breastfeeding women, and those taking other medications should consult with their healthcare provider or pharmacist for guidance on its appropriate use and potential interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 5.4 | 0.9 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 3 | 0.13 |
| Allergies | 7.6 | 3.5 | 1.17 |
| Allergy to milk products | 2 | 1.6 | 0.25 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.7 | 8 | -0.19 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.2 | 0.9 | 2.56 |
| Ankylosing spondylitis | 4.8 | 1.8 | 1.67 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 6.5 | 2.3 | 1.83 |
| Atherosclerosis | 2.7 | 2.5 | 0.08 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 10.8 | 10.8 | 0 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.6 | 3.8 | -0.06 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 6.6 | 7.5 | -0.14 |
| Chronic Kidney Disease | 5.2 | 2.9 | 0.79 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 2 | 0.5 |
| Chronic Urticaria (Hives) | 2 | 1.2 | 0.67 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 9.3 | 2.8 | 2.32 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 11.5 | 13.8 | -0.2 |
| Crohn's Disease | 9.9 | 5.8 | 0.71 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 3.7 | 1.4 | 1.64 |
| Denture Wearers Oral Shifts | 1.8 | 1.8 | |
| Depression | 12.9 | 9.9 | 0.3 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.6 | -0.13 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4 | 1.7 | 1.35 |
| erectile dysfunction | 2.6 | 0.3 | 7.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.3 | 1.1 | 2.91 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.4 | 2.5 | 0.36 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 0.8 | 1.63 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.5 | -0.67 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 3.9 | 1.8 | 1.17 |
| Heart Failure | 5.4 | 1.9 | 1.84 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 1.1 | |
| hyperglycemia | 2.1 | 1.1 | 0.91 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.7 | 6.3 | -0.34 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 3.6 | 0.9 | 3 |
| IgA nephropathy (IgAN) | 1.9 | 5.2 | -1.74 |
| Inflammatory Bowel Disease | 11.1 | 10.7 | 0.04 |
| Insomnia | 2.5 | 2.4 | 0.04 |
| Intelligence | 2 | 0.6 | 2.33 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 8.6 | 5.3 | 0.62 |
| ischemic stroke | 3.2 | 1.7 | 0.88 |
| Liver Cirrhosis | 8.4 | 4.2 | 1 |
| Long COVID | 8.2 | 8.8 | -0.07 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1 | 0.5 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.5 | 3.2 |
| Metabolic Syndrome | 8.7 | 8.5 | 0.02 |
| Mood Disorders | 12 | 8.4 | 0.43 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 7.9 | 7 | 0.13 |
| Multiple system atrophy (MSA) | 1.2 | 0.7 | 0.71 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 0.7 | 2.8 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.5 | 4.8 | 0.35 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 11.7 | 8.9 | 0.31 |
| obsessive-compulsive disorder | 7 | 4.2 | 0.67 |
| Osteoarthritis | 3.3 | 1.2 | 1.75 |
| Osteoporosis | 2.5 | 1.3 | 0.92 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 8.9 | 8.3 | 0.07 |
| Polycystic ovary syndrome | 7.9 | 3.2 | 1.47 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 2.7 | 3.2 | -0.19 |
| Psoriasis | 3.9 | 3.4 | 0.15 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.1 | 4.7 | 0.94 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 7 | 3.1 | 1.26 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 2.9 | 3.2 | -0.1 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.6 | 2.67 |
| Stress / posttraumatic stress disorder | 3.2 | 2.7 | 0.19 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 4.5 | 4.4 | 0.02 |
| Type 2 Diabetes | 10 | 8.5 | 0.18 |
| Ulcerative colitis | 7.3 | 7.7 | -0.05 |
| Unhealthy Ageing | 6.8 | 2.4 | 1.83 |
| Vitiligo | 2.5 | 1.5 | 0.67 |
